Pramine

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more

Treatment

20 Active Studies for Pramine

What is Pramine

Imipramine

The Generic name of this drug

Treatment Summary

Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively [A6584]. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) [L1349,L1348,A31900,L1351,L1352,L1353,A31904].

Tofranil

is the brand name

Pramine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tofranil

Imipramine

1959

103

When to interrupt dosage

The proposed dosage of Pramine is contingent upon the diagnosed condition. The degree of dosage is dependent on the method of administration outlined in the table beneath.

Condition

Dosage

Administration

Nocturnal Enuresis (bedwetting)

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Neuropathic Pain

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Panic Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Bulimia Nervosa

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Depression

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Attention Deficit Hyperactivity Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Warnings

Pramine Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Pramine.

Common Pramine Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.

Alfuzosin

Major

Imipramine may increase the hypotensive activities of Alfuzosin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Imipramine.

Amoxapine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Pramine Novel Uses: Which Conditions Have a Clinical Trial Featuring Pramine?

Currently, there are no clinical trials evaluating the utility of Pramine for any particular condition.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

61 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Nocturnal Enuresis (bedwetting)

2 Actively Recruiting

Not Applicable

Depression

290 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Bulimia Nervosa

0 Actively Recruiting

Panic Disorder

12 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Patient Q&A Section about pramine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How often can you take Pramin?

"It is best to take Pramin 30 minutes before nausea or vomiting is likely to occur, or 30 minutes before meals. doses of Pramin should be spaced evenly throughout the day, and it is only necessary to take Pramin when required for each occasion of nausea or vomiting."

Answered by AI

Does Pramin make you sleepy?

"Pramin could lead to drowsiness, dizziness, or lightheadedness for some individuals. If you experience any of these symptoms, do not operate any machinery or do anything else that could be harmful."

Answered by AI

What is the drug Paxlovid used for?

"Paxlovid is an oral antiviral pill that is taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized."

Answered by AI

What is Pramine used for?

"Pramine 25 MG Tablet is an antidepressant medicine that is used to treat psychological conditions like obsessive-compulsive disorder, depression, and anxiety disorders like panic attacks. It is also used to treat muscle weakness associated with a sleep disorder called narcolepsy."

Answered by AI

Clinical Trials for Pramine

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Pramine clinical trials?

We made a collection of clinical trials featuring Pramine, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Have you considered Pramine clinical trials?

We made a collection of clinical trials featuring Pramine, we think they might fit your search criteria.
Go to Trials
Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Pramine clinical trials?

We made a collection of clinical trials featuring Pramine, we think they might fit your search criteria.
Go to Trials